Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-Claudin18.2 antibody-drug conjugate IBI343

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration, anti-CLDN18.2 ADC IBI343 specifically targets and binds to CLDN18.2 expressed on tumor cells. Upon internalization, the cytotoxic agent induces apoptosis in CLDN18.2-expressing tumor cells through an as of yet unidentified mechanism of action (MoA). CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC IBI343
anti-CLDN18.2 ADC IBI343
Code name:IBI 343
IBI-343
IBI343
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search